Arbutus Biopharma
ABUS
55 hedge funds and large institutions have $29.7M invested in Arbutus Biopharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 14 closing their positions.
2.9% less ownership
Funds ownership: 37.14% → 34.24% (-2.9%)
11% less funds holding
Funds holding: 62 → 55 (-7)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
70% less capital inflows, than outflows
Capital inflows: $1.46M | Capital outflows: $4.87M
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$442K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$241K |
| 3 |
Jennison Associates
New York
|
+$236K |
| 4 |
Winton Group
London,
United Kingdom
|
+$141K |
| 5 |
ExodusPoint Capital Management
New York
|
+$68.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Foresite Capital Management IV
Larkspur,
California
|
-$1.26M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$610K |
| 3 |
JP Morgan Chase
New York
|
-$360K |
| 4 |
Jane Street
New York
|
-$348K |
| 5 |
Paloma Partners
Greenwich,
Connecticut
|
-$327K |
ABUS Hedge Fund Activity: Q3 2019 in Review
55 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2019, worth a combined $29.7M — down 33% from $44M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ABUS and 7 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 10 added.
The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $442K. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $1.26M sold.
- 55 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2019, down from 62 in Q2 2019.
- Funds reported $29.7M of Arbutus Biopharma stock for Q3 2019, down 33% quarter-over-quarter.
- 7 funds opened new Arbutus Biopharma positions in Q3 2019 and 14 closed out, a net change of -7 holders.
- The largest Arbutus Biopharma buyer in Q3 2019 was Bank of New York Mellon, an estimated $442K added.
- The largest Arbutus Biopharma seller in Q3 2019 was Foresite Capital Management IV, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2019.